Xenetic biosciences, inc. (XBIO)
Income statement / Yearly
Dec'19Dec'18Dec'17Dec'16Dec'15Dec'14Dec'13Aug'13Dec'12Aug'12
Revenue
Licenses

-

-

7,500

0

-

-

-

-

-

-

Milestones

-

-

0

3,000

0

-

-

-

-

-

Collaboration services

-

-

85

0

-

-

-

-

-

-

Total revenues

17

0

7,585

3,000

0

-

1,000

96

293

112

Gross profit

-

-

-

-

-

-

1,000

-

248

-

Operating costs and expenses:
Cost of research and development revenue

-

-

156

0

-

0

-

-

-

-

Cost of research and development revenue

-

-

-

-

-

-

-

-

44

-

Research and development

4,889

2,883

4,060

43,737

3,434

6,323

3,060

-

1,943

-

General and administrative

4,731

4,392

6,937

6,692

6,388

6,600

6,553

-

3,561

-

Goodwill impairment (Note 6)

3,283

0

-

-

-

-

-

-

-

-

Impairment of In-Process Research and Development

-

-

-

-

-

-

-

-

1,087

-

Aircraft maintenance and fee

-

-

-

-

-

-

-

9

-

36

Fuel and oil

-

-

-

-

-

-

-

8

-

27

Management fees

-

-

-

-

-

-

-

4

-

19

Officer compensation

-

-

-

-

-

-

-

15

-

0

Professional fees

-

-

-

-

-

-

-

78

-

126

Depreciation and amortization

-

-

-

-

-

-

-

38

-

19

Administrative fees

-

-

-

-

-

-

-

7

-

0

Total operating costs and expenses

12,903

7,276

-

-

-

-

9,613

162

6,593

229

Loss from operations

-12,886

-7,276

-3,568

-47,430

-9,822

-12,924

-8,613

-65

-6,344

-116

Other income (expense):
Change in fair value of derviative liability

-

-

0

2,125

-2,125

0

-

-

-

-

Loss on issuance of hybrid debt instruments

-

-

-

-

-59

-

-

-

-

-

Loss on issuance of hybrid debt instruments

-

-

0

-1,690

-

-

-

-

-

-

Loss on issuance of hybrid debt instrument

-

-

-

-

-

0

-

-

-

-

Loss on disposal of subsidiaries

-

-

-

-

-

-1,069

-

-

-

-

Loss on conversion of debt

-

-

0

-6,394

0

-

-

-

-

-

Other expense

3

-24

-41

-85

-235

-326

34

-

15

-

Interest income, net

108

0

-

-

-

-

-

-

-

-

Other expense

-

-

-

-

-

-

-

-23

-

-13

Interest income

-

-

16

0

1

18

-

-

-

-

(Gain) loss on settlement

-

-

-

-

-

-

-

10

-

-

Interest expense

-

-

1

729

266

4

0

-12

51

-13

Interest income

-

-

-

-

-

-

34

-

67

-

Total other income (expense)

111

-24

-26

-6,775

-2,685

-1,382

-

-

-

-

Loss before income taxes

-

-

-

-

-

-

-8,579

-

-6,328

-

Income tax

-

-

-

-

-

-

0

-

0

-

Net loss

-12,775

-7,300

-3,595

-54,206

-12,507

-14,307

-

-

-

-

Deemed dividend

5,284

0

-

-

-

-

-

-

-

-

Accretion of beneficial conversion feature on convertible preferred stock

-

-

0

4,035

0

-

-

-

-

-

Net loss applicable to common stockholders

-18,059

-7,300

-3,595

-58,241

-12,507

-

-

-

-

-

Net loss

-

-

-

-

-

-

-8,579

-

-6,328

-

Other comprehensive loss from foreign currency translation adjustment

-

-

-

-

-321

-324

-15

-

1,170

-

Total comprehensive loss

-

-

-3,595

-54,206

-12,829

-14,631

-8,594

-

-5,157

-

Net income (loss)

-

-

-

-

-

-

-

-89

-

-129

Basic and diluted loss per share

-6.33

-9.66

-0.41

-7.84

-2.96

-0.11

-0.07

0.00

-0.05

-0.01

Weighted-average shares of common stock outstanding, basic and diluted

2,852

756

8,665

7,430

4,223

135,896

119,836

-

119,828

-

Weighted average shares outstanding

-

-

-

-

-

-

-

135,000

-

144,153

Royalty [Member]
Total revenues

17

0

-

-

-

-

-

-

-

-